Background-Ablation of complex fractionated atrial electrograms (CFAEs) has been proposed as a strategy to improve outcomes in atrial fibrillation (AF) catheter ablation, but the use of this technique remains contentious. We aimed to assess the impact of CFAE ablation in addition to pulmonary vein isolation (PVI) in patients undergoing ablation for AF. Methods and Results-We performed a random effects meta-analysis of studies comparing PVI versus PVI+CFAE ablation.
C atheter ablation is now an established treatment for patients with symptomatic drug-refractory atrial fibrillation (AF; class I, level of evidence A). 1, 2 
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After the seminal work of Haïssaguerre et al 3 demonstrating that AF could be triggered by pulmonary ectopy, strategies targeting the pulmonary veins have become the cornerstone for AF catheter ablation procedures. 4 However, those studies also showed that relapses occur in ≤30% of paroxysmal AF patients in the first year and 70% of patients with persistent AF even when all the pulmonary veins are successfully isolated. 5 The focus has subsequently shifted to targeting areas of abnormal left atrial tissue which may act as a substrate for sustaining AF episodes in addition to pulmonary vein isolation. Complex fractionated atrial electrograms (CFAEs) have emerged as one of the possible sources for sustaining AF and CFAE ablation has become a widespread adjuvant strategy in ablation. 6 Despite joint Heart Rhythm Society, European Heart Rhythm Association and European Cardiac Arrhythmia Society Consensus recommendations endorsing more extensive ablation for persistent AF, including targeting CFAEs±linear ablation, 4 evidence to support the incremental benefit of CFAE ablation remains largely absent. 7, 8 This metaanalysis aims to assess the impact of additional CFAE ablation in patients undergoing pulmonary vein isolation (PVI) for ablation of AF.
Methods

Study Selection
We performed searches on MEDLINE (via PubMED), EMBASE, clinicaltrials.gov, and COCHRANE databases (from inception to November 30, 2014) using the following search string: AF and catheter ablation and (CFAE or complex fractionated atrial electrograms).
Reference lists of all accessed full-text articles were further searched for sources of potentially relevant information. The authors of full-text papers and congress abstract authors were also contacted by e-mail to retrieve additional information.
Only longitudinal studies performed in humans were considered for inclusion. The population, intervention, comparison and outcome (PICO) approach was used. 9 The population of interest included patients with AF and the intervention was catheter ablation of AF, consisting of PVI and optional CFAE ablation. Comparisons were performed between patients receiving PVI versus PVI plus CFAE ablation. The outcomes were freedom from AF or atrial tachycardia (AT) recurrence; ablation-related complications.
Minimum follow-up duration was 6 months. Both registries and randomized trials were considered eligible for analysis. Empirical ablation of lines was allowed if this was performed as part of the ablation protocol in both treatment groups. The Methods section of evaluated studies was reviewed to confirm the suitability and composition of the reported end point.
To be eligible, studies needed to present matched control-groups and the only difference in the treatment strategy had to be performing CFAE ablation in 1 group and no CFAE ablation in the comparator. If other differences between treatment groups were observed in the study protocol (eg, use of different mapping or imaging systems; comparisons of patients with persistent AF converting to sinus rhythm while having their PVI versus patients remaining in AF after PVI), the study was not considered appropriate for inclusion. If at least 3 treatment groups were present in the study, and only 1 of them was considered inadequate, the study could still be considered eligible and data of the 2 appropriate treatment groups included. Full-text articles remaining unpublished >3 years after initial congress abstract presentation were not considered appropriate for inclusion.
The definitions of AF or AT relapse, blanking period, and methods used for monitoring during follow-up were collected in all studies. The following events were considered ablation-related complications and their incidence in both treatment groups was assessed: cardiac tamponade or pericardial effusion requiring pericardiocentesis, stroke or transient ischemic attack, atrio-oesophageal fistula, and pulmonary vein stenosis.
Three independent reviewers (R.P., N.S., and G.B.) screened all abstracts and titles to identify potentially eligible studies. The full text of these potentially eligible studies was then evaluated to determine the eligibility of the study for the review and meta-analysis. Agreement of at least 2 reviewers was required for decisions about inclusion or exclusion of studies. Study quality was formally evaluated using the Delphi Consensus criteria for randomized controlled trials 10 and a modified Newcastle-Ottawa Quality Assessment Scale for Cohort Studies 11 by 3 reviewers (R.P., N.S., and G.B.). An agreement between the 3 reviewers was mandatory for the final classification of studies.
Data extraction and presentation for the preparation of this article followed the recommendations of the PRISMA group. 12 The following data were extracted for characterizing each patient sample in the selected studies, whenever available: demographics and sample characterization, AF duration, presence of structural heart disease, atrial size, ablation technique and criteria for defining CFAE, location of ablated CFAE, follow-up duration, number of procedures, monitoring of AF relapse, and use of antiarrhythmic agents.
Statistical Analysis
Data were pooled using random effects, according to the Mantel-Haenszel model, through Review Manager (RevMan), version 5.1. (Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2011). The odds ratio (OR) and respective 95% confidence interval (95% CI) were used as a measurement of treatment effect. Pairwise comparisons were performed for the end points: AF/AT relapse and ablation-related complications.
To assess study design-related factors potentially interfering with the results of the meta-analysis, several sensitivity analyses were performed to assess the impact of baseline differences in the population, study design, CFAE mapping and treatment approaches, and followup in the AT or AF relapse outcomes. Sensitivity analyses were only performed for conditions fulfilled by at least 2 studies and gathering at least 15% of the whole meta-analysis population.
Statistical heterogeneity on each outcome of interest was quantified using the I 2 statistic. The I 2 statistic describes the percentage of total variation across studies because of heterogeneity rather than chance. Values of <25%, 25% to 50%, and >50% are by convention classified low, moderate, and high degrees of heterogeneity, respectively.
Funnel plots and meta-regression analyses were obtained using Comprehensive Meta-Analysis software (version 2). Funnel plots were used for evaluating the presence of publication bias and traced for comparisons including >10 studies (minimum number for assuring the appropriateness of the method). 13 A meta-regression (using the unrestricted maximum likelihood method) was performed for comparisons involving >10 studies for assessing the possible association of modulator variables with the end point AF or AT relapse.
Heterogeneity-adjusted trial sequential analysis was applied to the meta-analysis to reduce the risk of random error because of repetitive testing of accumulating data. 14 The optimal information size with adaptation of monitoring boundaries, and the cumulative Z statistics after each trial were assessed. This was based on an α significance level of 5% and a β of 20% (80% power), an expected reduction in AT or AF relapse of 30% and a 50% increase in complications, the observed incidence rate in the control group, and the variation across trials (I 2 ).
Results
Search Results
A total of 398 entries were retrieved for analysis of titles and abstracts. Of these, 374 were excluded as they were either duplicates or deemed unsuitable for the purpose of our metaanalysis (editorials, letters, reviews, or case reports). The remaining 24 results were carefully screened, and after analysis of their full-text, only 8 were considered adequate for the purpose of our meta-analysis. 7, [15] [16] [17] [18] [19] [20] [21] A careful review of their reference list provided 4 more entries that were selected after revision of the full text. [22] [23] [24] [25] Manual searches also provided 1 last entry, a randomized controlled trial recently published in a Hot-Line Session at a major cardiovascular meeting. 8 The selection process is illustrated in Figure 1 . There was an excellent agreement between investigators on the inclusion of the selected trials.
WHAT IS KNOWN
• Complex fractionated atrial electrograms (CFAEs) have emerged as one of the possible sources for sustaining atrial fibrillation, and CFAE ablation has become a widespread adjuvant strategy in ablation.
• The impact of CFAE ablation in addition to pulmonary vein isolation in patients undergoing catheter ablation of atrial fibrillation is still controversial.
WHAT THE STUDY ADDS
• CFAE ablation seems to be safe. • We failed to confirm the overall benefit of CFAE ablation in addition to pulmonary vein isolation.
Baseline data and the design of selected trials are summarized in Tables 1 and 2. The final population for this metaanalysis included 1415 patients (815 treated with PVI+CFAE ablation and 600 with PVI).
Nine studies were randomized controlled trials. 7, 8, 17, [19] [20] [21] [22] [23] [24] Of the 5 multicenter trials, 7, 8, 16, 17, 22 only 1 16 was nonrandomized. Quality assessment of the included studies is shown in Table I in the Data Supplement. Two randomized controlled studies had ≥6 Delphi criteria 7, 8 and all cohort studies had a Newcastle-Ottawa score of ≥7.
Treatment groups were balanced at baseline ( Table 1 ). Most studies had small patient samples, usually <100 participants. The percentage of persistent AF patients markedly differed between studies. In most studies, patients were in their fifties and AF had been diagnosed <5 to 6 years before ablation. In 1 study, the mean left atrium (LA) size was in the normal range, 20 whereas in the remainder a mild to moderate LA dilation was observed. In all studies, LA size was characterized according to a single linear dimension (diameter). Eligibility/patient selection criteria for each study are illustrated in Table 2 .
CFAE definition and the approach used for CFAE mapping and ablation in each trial are presented in Table 2 and Table II in the Data Supplement. Some studies used automatic algorithms incorporated into 3-dimensional mapping systems, 7, 8, 16, 18, 20, 24 whereas others relied on operator-guided analysis of electrograms. 15, 17, 19, [21] [22] [23] 25 Data about outpatient treatment, relapse definition, and follow-up in the different studies are shown in Table 3 . Mean follow-up duration was >12 months in the majority of studies. Most studies relied on clinical appointments, 12-lead ECG, and 24-or 48-hour Holter monitors for follow-up purposes. Some studies used external loop recorders 7, [15] [16] [17] [18] [19] 22, 23 or transtelephonic monitoring. 7, 8, 21, 24 Interrogation of existing cardiac devices was used in 3 studies, 7, 16, 22 but implantable loop recorders were not used routinely in any of the studies. During follow-up, patients underwent a mean of 1 to 1.4 ablation procedures.
Role of Additional CFAE Ablation and Outcomes
The pooled data of studies comparing PVI alone versus PVI+CFAE ablation showed a lack of significant benefit in favor of any treatment strategy in terms of freedom from AF or AT (PVI=29.7% versus PVI+CFAE=31.3%; OR, 0.80; 95% CI, 0.58-1.10; P=0.17). Only 2 studies showed benefits of the PVI+CFAE ablation strategy, 7, 25 whereas the remainder were neutral (Figure 2A ). While in Nam et al 25 data on AF duration was not provided and only persistent AF patients were treated, the Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF) 7 study included patients with longer AF duration from diagnosis and also a third of patients had high-burden paroxysmal AF.
The incidence of severe complications was low, usually <1 to 1.5%. More extensive ablation did not lead to an increase in procedural complications (PVI=1.5% versus PVI+CFAE=1.5%; OR, 1.06; 95% CI, 0.41-2.75; P=0.91; Figure 2B ).
The observed I 2 values showed moderate heterogeneity for freedom from AF/AT (I 2 =32%). Conversely, heterogeneity of procedural complications was low (I 2 =0%). Funnel plots ( Figure I in the Data Supplement) for the 2 main end points do not suggest the presence of selection bias. Figure 3A and 3B illustrates the necessary sample power to demonstrate a 30% reduction in AF or AT relapse and a 50% increase in complications in patients having CFAE ablation performed in addition to PVI. Despite failing to show a significant reduction in this end point, this meta-analysis was sufficiently powered to show a 30% reduction in AF or AT relapse using a more extensive ablation strategy (1011 patients needed). From a safety perspective, and despite the apparently reassuring data, a sample of 4891 patients would be required to statistically confirm that additional CFAE ablation does not lead to an increase in complications because of the low incidence of complications.
Sensitivity Analyses
Several scenarios were assessed to find specific subsets of patients or treatment approaches that could show the benefit of additional CFAE ablation in patients undergoing PVI (Table 4) .
When separately pooling data on nonrandomized studies, benefit was found in favor of PVI+CFAE ablation with a statistically significant almost 50% lower likelihood of AF or AT relapse: PVI+CFAE=15.0% versus PVI=25.5%; OR, 0.52; 95% CI, 0.31 to 0.86; P=0.01.
A trend for a 38% reduction in relapses in patients undergoing PVI+CFAE ablation who also had empirical linear ablation (at least 1 of the following: mitral isthmus, left atrial roof, cavotricuspid isthmus, or superior vena cava isolation) was also observed: PVI+CFAE±linear ablation=14.6% versus PVI±linear ablation=14.6%; OR, 0.62; 95% CI, 0.37 to 1.03; P=0.07. Sensitivity analysis of the remaining studies (those without empirical linear ablation) revealed no benefit of CFAE ablation: PVI+CFAE=37.2% versus PVI=34.1%; OR, 0.87; 95% CI, 0.57 to 1.31; P=0.49. All remaining assessed scenarios demonstrated no clear benefit of CFAE ablation.
Meta-Regression: Assessment of Moderator Variables
The assessment of potential moderator variables through metaregression is shown in Table III moderate association was found between longer duration AF (years since diagnosis) and greater clinical benefit from CFAE ablation performed in addition to PVI (r=0.38, Model Q=6.94, df=1, P=0.008; Figure 4 ). No other variables were associated with procedural outcomes.
Discussion
Two main conclusions can be drawn from this meta-analysis: (1) pooled results failed to confirm the overall benefit of CFAE ablation in addition to PVI in patients undergoing catheter ablation of AF; (2) CFAE ablation was associated with a low incidence of adverse effects, comparable with PVI alone, with the caveat that this meta-analysis was not sufficiently powered to definitively infer this.
Increasing evidence suggests that PVI with durable lesion formation (either using contact-force sensing catheters or the cryoballoon) seems to be a key in paroxysmal AF ablation, with success rates (freedom from AT or AF after a blanking period) of >80% at 12 months. 26 However, ablation of persistent AF still remains a challenge. A recent multicenter randomized controlled trial showed that catheter ablation was more effective than drug therapy as a rhythm control strategy, but almost 40% of patients presented with AF or AT relapses in the first 12 months. 27 In this trial, CFAE or linear ablation could be performed at the operators' discretion. We think this means there is considerable scope for improvement in overall success rates for persistent AF ablation.
Why Is CFAE Ablation of No Benefit?
There are several explanations for the observed lack of benefit of additional CFAE ablation. First, patients included in most studies often present with milder forms of AF (paroxysmal AF and recently diagnosed persistent AF), in which PVI alone by itself may be sufficient both in terms of treating triggers and reducing the critical mass of atrial tissue to maintain AF. 28 In most trials, the duration of AF episodes in persistent AF patients ranged from 7 days to >1 year. Such a broad definition is likely to include patients with different mechanisms and substrate for AF, and therefore likely variable potential for benefit from more extensive ablation strategies. Even though our meta-analyses lacked sufficient statistical power to confirm this hypothesis (only 2 studies 19, 22 focused on patients with long-standing persistent AF and no subanalyses are available regarding the duration of AF episodes), there was a moderate association between AF duration and benefit of additional CFAE ablation, implying that the longer AF has persisted, the more atrial remodelling has occurred and the greater benefit may be accrued by CFAE ablation.
Second, data in this study suggest that CFAE mapping and ablation is performed in a highly heterogeneous manner in different centers with subjective interoperator variance in the targeting of CFAEs. 29 Centers may also treat different forms of AF in similar ways, for example, patients with long-standing persistent AF being offered PVI alone, similar to those with true PAF. It is possible, therefore, that we are simultaneously targeting different types of signals which play different roles in AF perpetuation. Even when automatic mapping systems are used, there are differences in their set up and algorithms for classifying fractionated electrograms ( Table II in the Data Supplement) and this is even more heterogeneous and subjective in manually derived CFAE definitions with fractionation intervals ranging from <50 to <120 ms and with no consensus on how CFAE signals should be mapped/acquired. It has been shown, using a rigorously defined visual scale for assessing progressive degrees of fractionation, that not all types of atrial fractionated signals have the same influence in AF maintenance, and that targeting zones of continuous activity can lead to more pronounced increases in AF cycle length. 30 However, a consensus definition of CFAEs and which type of electrograms should be ablated are yet to be defined. Similarly, there is evidence that CFAEs may vary temporally and spatially, 31 and the timeframe over which CFAEs should be acquired is not defined and varies between studies. The type of catheters used and the contact force used is also variable without a standardized approach.
Third, it is still not known whether CFAEs represent areas of atrial myocardium critical to AF maintenance or simply areas of passive activation because of wavebreak. Thus, is CFAE ablation merely an exercise in atrial debulking or does it really hit the eye of the storm, removing critical elements involved in the triggering or sustaining AF and result in electric organization into re-entrant ATs and eventually sinus rhythm? It is possible that common locations for CFAEs (atrial septum, close to the pulmonary veins, and left atrial appendage) are coincidentally adjacent to parasympathetic ganglia 32 or that CFAE ablation causes AF termination just by chance. However, Hunter et al think that CFAE ablation is not merely debulking the atria and have proposed that grading CFAEs according to the degree of fractionation may be of importance, as not all CFAEs seem to play the same role in AF perpetuation. 30 The results of that study, and the recent SELECT-AF trial, 33 seem to show that selectively targeting areas of complex continuous fractionated electrograms may impact positively AF ablation results in the acute and midterm setting. However, this technique requires further investigation and confirmation from large randomized studies, especially in light of the results of this meta-analysis. Understanding the true mechanism of CFAEs is probably the only way to confirm the rationale to continue targeting them or a good reason to stop.
Despite the results of the present meta-analysis, it is intriguing that adjunctive CFAE ablation increases the chances of organization into AT or conversion to sinus rhythm. 19 Data also suggest that termination of persistent AF during catheter ablation is a predictor of long-term success. 34 It would therefore be expected that CFAE ablation in addition to PVI might result in better long-term outcomes. However, the seemingly helpful acute results of CFAE ablation are not borne out on long-term follow-up. It is possible that in failing to produce transmural lesions, gap formation and recovery occur, or that relapses are related to PVI reconnection rather than unsuccessful CFAE elimination. It is possible that contact forcesensing catheters may lead to an improvement in outcomes. These catheters have already shown to be effective in improving lesion formation 35 and the outcomes of paroxysmal AF ablation. 36 Another explanation is that recurrence occurs because of progression of atrial disease, with development of further fibrosis and arrhythmogenic triggers leading to arrhythmia relapse requiring further ablation.
Is CFAE Ablation of Any Interest?
Evidence suggests that additional CFAE ablation leads to an increase in procedure duration (procedures last at least 1 hour longer). 8 On this basis, the results of this meta-analysis, probably it is not necessary to perform CFAE ablation in every patient undergoing AF ablation. CFAE ablation is, however, safe and should be considered in patients where a high likelihood of AF relapse is expected with PVI alone. Our data suggest that patients with longer AF duration may be most likely to benefit the most from more extensive ablation. Whether they should have additional CFAE ablation in addition to PVI or linear ablation using the step-wise Bordeaux approach 37 is unclear. Our data show a trend in favor of this approach, with CFAE ablation being apparently more beneficial if performed alongside PVI and lines, but this needs to be investigated in a randomized clinical trial.
Whether or not, performing CFAE ablation can be of benefit in patients with a more severe substrate or dilated left atria is still an open question. Data provided in the included studies did not allow us to perform a sensitivity analyses on this matter. On meta-regression, LA size (in mm) was not associated with procedural success. However, LA diameter is known to be an inappropriate and outdated method, and the current recommendations of the European Association of Echocardiography and American Society of Echocardiography support measuring LA biplane volume using either the area-length formula or the modified Simpson's rule as the preferred method for assessing LA size. 38 Therefore, it is still to be clarified if we found no association between a possible benefit of additional CFAE according to LA size simply because it does not exist or just because we have used an inexact way to assess the LA.
Role of Other Treatment Strategies
Targeting rotors, 39 ganglia, 40 or using other mapping algorithms based on electrograms, like dominant frequency 41 or different signal processing algorithms for accessing CFAEs, 42 needs to be ascertained.
In patients with advanced forms of AF, a combined treatment approach is required, targeting not only substrate and triggers but also optimization of medical therapy, 43 in a similar manner to the treatment of hypertension and heart failure with combination therapy, whereas addressing risk factors 44 and focusing on the correction of diseases triggering AF, such as sleep apnoea.
More studies are needed to address the questions raised by this meta-analysis. Four questions deserve special attention: (1) Do CFAEs play a role in the maintenance of AF? (2) What is the best method to detect and eliminate CFAEs? (3) Which patients benefit most from CFAE ablation (if any)? and (4) Are there more effective alternatives?
Limitations
Several limitations are commonly linked to the methodology of meta-analyses, principally heterogeneity between studies analyzed. In this case, however, heterogeneity, assessed through the I 2 test, was low for the pooled analysis of complications and low to moderate for AT or AF relapse. This supports the notion that the majority of the included studies share many commonalities. Also, to address this limitation, we assessed the modulating effect of baseline differences in the different study populations through meta-regression. Some other limitations should be highlighted. First, this meta-analysis was not sufficiently powered to show differences about complication rate. In spite of this, these initial data seem reassuring in this context. The observed low incidence of complications in both treatment groups implies studies of several thousand patients would be necessary to clearly demonstrate the safety of CFAE ablation. Second, only a minority of studies presented data allowing sensitivity analysis of patients with long-standing persistent AF. Therefore, we were not able to provide conclusive evidence of benefit of CFAE ablation in this group of patients, who are likely to be the subgroup to benefit most from this intervention. Third, overall study quality can be considered low, as only 2 randomized controlled trials with a Delphi score of ≥6 were identified and included for analysis. Fourth, the definition of CFAE varied widely among the different studies. This heterogeneity in methodology could have influenced the results of the analysis but likely reflects current real-world practice highlighting the lack of consensus on what a CFAE is. We attempted to assess this through a sensitivity analysis on visual inspection methods and automated algorithms ( Table 4 ) and found no significant differences in these approaches. Finally, the CFAE ablation protocol ( Table  II in the Data Supplement) differed among studies. The extent of CFAE ablation may have a role in procedural outcomes and needs to be addressed further in a randomized study.
Conclusions
Although associated with a low incidence of adverse events, adjunctive CFAE ablation in patients undergoing PVI was not associated with an increase in the overall medium-term success rate of catheter ablation for paroxysmal or persistent AF.
Our data suggest a possible benefit of this intervention in patients with more advanced forms of AF (those with longer AF duration). However, this requires confirmation in randomized controlled trials.
Other alternatives should be assessed to improve the outcome of AF ablation.
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